Strategies to genetically engineer T cells for cancer immunotherapy Timothy T. SpearKaoru NagatoMichael I. Nishimura Review 02 May 2016 Pages: 631 - 649
Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma Fergus NobleToby MellowsChristian H. Ottensmeier Original Article Open access 28 March 2016 Pages: 651 - 662
2′–5′ Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons Chan Kyu SimYeon Sook ChoMyeong Sup Lee Original Article 31 March 2016 Pages: 663 - 675
Endostatin inhibits the growth and migration of 4T1 mouse breast cancer cells by skewing macrophage polarity toward the M1 phenotype Hua GuoYanan LiuYang Li Original Article 31 March 2016 Pages: 677 - 688
Differential immunomodulatory activity of tumor cell death induced by cancer therapeutic toll-like receptor ligands Johanna C. KleinClarissa A. WildSven Brandau Original Article 31 March 2016 Pages: 689 - 700
Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer Federica CappucciniStephen StribblingIrina Redchenko Original Article Open access 06 April 2016 Pages: 701 - 713
Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma Eishiro MizukoshiTatsuya YamashitaShuichi Kaneko Original Article 15 April 2016 Pages: 715 - 725
Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion Stephanie Du FourSarah K. MaenhoutJoeri L. Aerts Original Article 20 April 2016 Pages: 727 - 740
Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells Akhil ChawlaGheath AlatrashElizabeth A. Mittendorf Original Article 29 April 2016 Pages: 741 - 751
Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma Paula KroonJules GadiotInge Verbrugge Original Article Open access 09 May 2016 Pages: 753 - 763
A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome Elizabeth HansenDeepak SahasrabudheLynn Sievert Letter to the Editors 11 April 2016 Pages: 765 - 767
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors “A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome” Lavinia SpainJames LarkinJuan Martin-Liberal Letter to the Editors 19 May 2016 Pages: 769 - 770